SimBioSys, Magic Leap Team Up on Surgical Oncology Treatment

SimBioSys is partnering with Magic Leap Inc. to potentially fuse cutting-edge technologies to improve cancer treatment.

The pairing will combine SimBioSys’ expertise in medical imaging artificial intelligence (AI) evaluation with Magic Leap’s augmented reality (AR) technology to help surgeons better optimize surgical precision, minimize invasiveness, and ultimately improve patient quality of life.
 
SimBioSys’ newly U.S. Food and Drug Administration (FDA)-cleared product, TumorSight Viz, provides surgical oncologists with 3D spatial visualizations and key insights of breast cancer on a web-browser, giving clinicians a more comprehensive understanding of the cancer and supporting more effective patient consultations. Through this collaboration, the companies will explore the integration of TumorSight Viz into Magic Leap 2’s AR product, revolutionizing the ways in which surgeons can interact with and understand a patient-specific case. By enabling viewing on immersive AR, surgeons can gain insight into tumor localization and surrounding anatomy, supporting more informed treatment decision-making and enhanced patient outcomes.
 
“Like AI, the AR field has made incredible strides in recent years, with Magic Leap being a recognized market leader and trailblazer in the space,” SimBioSys Chief Medical Officer and breast surgical oncologist Barry Rosen, M.D., said. “Unfortunately, other VR/AR approaches have failed in modalities such as breast cancer where the imaging does not reflect the patient’s position at surgery. SimBioSys has solutions coming to market soon that can adjust for this with our computation modeling capabilities and can help power AR in breast cancer to have real clinical utility.”
 
Magic Leap 2 is an enterprise-ready AR device designed to seamlessly bridge the gap between physical and digital worlds. The first demonstrations of the dual technologies were shown earlier this spring. The integrated SimBioSys and Magic Leap 2 workflow is currently for educational purposes only and not FDA cleared (or otherwise cleared) for diagnostic use or other uses.
 
SimBioSys harnesses the power of spatial biophysics with artificial intelligence and computational modeling to redefine precision medicine, improve patient care and defeat cancer. By seeing cancer more completely, SimBioSys aims to empower clinicians, patients, and researchers with a more informed understanding of a patient’s tumor to optimally assess all available options. 
 
Magic Leap’s technology is designed to amplify human potential by delivering the most immersive AR platform so people can intuitively see, hear, and touch digital content in the physical world. Through the use of its advanced, enterprise-grade AR technologies, products, platforms, and services, the firm delivers businesses a tool for transformation. Founded in 2010, Magic Leap is headquartered in South Florida, with eight additional offices worldwide.